BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18443125)

  • 1. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.
    Fransen S; Bridger G; Whitcomb JM; Toma J; Stawiski E; Parkin N; Petropoulos CJ; Huang W
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2608-15. PubMed ID: 18443125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
    Esté JA; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
    J Virol; 1999 Jul; 73(7):5577-85. PubMed ID: 10364306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies.
    Singh A; Collman RG
    J Virol; 2000 Nov; 74(21):10229-35. PubMed ID: 11024154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.
    Fernàndez G; Llano A; Esgleas M; Clotet B; Esté JA; Martínez MA
    J Gen Virol; 2006 May; 87(Pt 5):1285-1294. PubMed ID: 16603531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.
    Cilliers T; Nhlapo J; Coetzer M; Orlovic D; Ketas T; Olson WC; Moore JP; Trkola A; Morris L
    J Virol; 2003 Apr; 77(7):4449-56. PubMed ID: 12634405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
    Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
    J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.
    Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM
    J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists.
    Stalmeijer EH; Van Rij RP; Boeser-Nunnink B; Visser JA; Naarding MA; Schols D; Schuitemaker H
    J Virol; 2004 Mar; 78(6):2722-8. PubMed ID: 14990692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
    Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
    J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals.
    Pollakis G; Abebe A; Kliphuis A; Chalaby MI; Bakker M; Mengistu Y; Brouwer M; Goudsmit J; Schuitemaker H; Paxton WA
    J Virol; 2004 Mar; 78(6):2841-52. PubMed ID: 14990703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1.
    Bader J; Däumer M; Schöni-Affolter F; Böni J; Gorgievski-Hrisoho M; Martinetti G; Thielen A; Klimkait T;
    Clin Infect Dis; 2017 Feb; 64(3):295-300. PubMed ID: 27838645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones.
    Ariën KK; Gali Y; El-Abdellati A; Heyndrickx L; Janssens W; Vanham G
    Virology; 2006 Mar; 347(1):65-74. PubMed ID: 16386774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan mother-infant pairs.
    Huang W; Eshleman SH; Toma J; Stawiski E; Whitcomb JM; Jackson JB; Guay L; Musoke P; Parkin N; Petropoulos CJ
    AIDS; 2009 Sep; 23(14):1903-8. PubMed ID: 19593079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.
    Surdo M; Balestra E; Saccomandi P; Di Santo F; Montano M; Di Carlo D; Sarmati L; Aquaro S; Andreoni M; Svicher V; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2013; 8(7):e68076. PubMed ID: 23874501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4.
    Cho MW; Lee MK; Carney MC; Berson JF; Doms RW; Martin MA
    J Virol; 1998 Mar; 72(3):2509-15. PubMed ID: 9499115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma.
    Soulié C; Tubiana R; Simon A; Lambert-Niclot S; Malet I; Canestri A; Brunet C; Murphy R; Katlama C; Calvez V; Marcelin AG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):60-4. PubMed ID: 19390328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors.
    Pontow S; Ratner L
    J Virol; 2001 Dec; 75(23):11503-14. PubMed ID: 11689632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced fitness of HIV-1 resistant to CXCR4 antagonists.
    Armand-Ugón M; Quiñones-Mateu ME; Gutiérez A; Barretina J; Blanco J; Schols D; De Clercq E; Clotet B; Esté JA
    Antivir Ther; 2003 Feb; 8(1):1-8. PubMed ID: 12713058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands.
    Ghezzi S; Menzo S; Brambilla A; Bordignon PP; Lorini AL; Clementi M; Poli G; Vicenzi E
    Virology; 2001 Feb; 280(2):253-61. PubMed ID: 11162839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.